zotarolimus + dual antiplatelet therapy

**Zotarolimus + dual antiplatelet therapy** is a combination regimen commonly used for patients receiving zotarolimus-eluting coronary stents. **Zotarolimus** is a semi-synthetic immunosuppressant and analog of sirolimus (rapamycin), developed to inhibit smooth muscle cell proliferation and prevent restenosis following stenting.[1][3][5] It is delivered locally via a polymer-coated stent, where its cytostatic activity suppresses neointimal hyperplasia. The dual antiplatelet therapy (DAPT) component refers to the use of two agents—typically aspirin (a cyclooxygenase-1 inhibitor) and an oral P2Y12 receptor inhibitor (clopidogrel, prasugrel, ticagrelor, or cangrelor)—which synergistically block key pathways in platelet aggregation to reduce the risk of thrombotic events post stent implantation.[2][4][6] This combination is standard care after percutaneous coronary intervention with drug-eluting stents due to its proven efficacy in preventing stent thrombosis and other major cardiovascular events while balancing bleeding risks.[2][3][5]

Brand names

EndeavorResoluteResolute IntegrityResolute OnyxOnyx Frontier

Other names

(42S)-42-Deoxy-42-(1H-tetrazol-1-yl)-rapamycin + dual antiplatelet therapy